Abstract
Malignant neoplasms of salivary gland neoplasms are rare and often involve the parotid gland. The primary treatment of these malignancies is surgery with or without adjuvant therapy. Chemotherapy or systemic therapy is indicated in recurrent or metastatic disease where surgery or radiotherapy is not possible. Salivary gland carcinomas, which are human epidermal growth factor receptor 2 (HER2) positive, show an aggressive behaviour with a poor prognosis. Targeting the HER2 pathway with drugs designed to block this pathway is an interesting novel therapy to treat salivary gland carcinomas. We report a case of a patient with HER 2-overexpressing parotid gland adenocarcinoma with brain metastasis, who was managed with ado-trastuzumab emtansine (T-DM1): a monoclonal antibody-cytotoxic drug conjugate that combines trastuzumab with the microtubule inhibitor, emtansine. The patient showed excellent response to the therapy. This case highlights the role of systemic chemotherapy with T-DM1 in HER2 positive salivary gland tumours that could be considered a part of the treatment regimen.
Reference12 articles.
1. [WHO classification of head and neck tumours 2017: Main novelties and update of diagnostic methods];Sarradin;Bull Cancer,2018
2. Maintenance therapy with trastuzumab in HER2 positive metastatic parotid ductal adenocarcinoma;Iqbal;Case Rep Oncol Med,2014
3. Second-Line treatment of HER2-positive salivary gland tumor: Ado-Trastuzumab emtansine (T-DM1) after progression on trastuzumab;Corrêa;Case Rep Oncol,2018
4. Cohen MJ . T-DM1: proof HER2 is a target in salivary gland cancers. Proceedings of UCLA Healthcare 2017;21.
5. Targeting HER2/neu oncogene overexpression with Ado-Trastuzumab emtansine in the treatment of metastatic salivary gland neoplasms: a single-institution experience;Swed;JCO Precis Oncol,2019
Cited by
2 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献